The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis

Samar M. Said, Alejandro Best Rocha, Anthony M. Valeri, Paisit Paueksakon, Surendra Dasari, Jason D. Theis, Julie A. Vrana, Modupe O. Obadina, Darius Saghafi, Mariam Priya Alexander, Sanjeev Sethi, Christopher P. Larsen, Florent Joly, Angela Dispenzieri, Frank Bridoux, Christophe Sirac, Nelson Leung, Agnes B. Fogo, Ellen D. McPhail, Samih H. Nasr

Research output: Contribution to journalArticlepeer-review


The type of monoclonal light chain nephropathy is thought to be largely a function of the structural and physiochemical properties of light chains; hence most affected patients have only one light chain kidney disease type. Here, we report the first series of kidney light chain deposition disease (LCDD) concomitant with light chain amyloidosis (LCDD+AL), with or without light chain cast nephropathy (LCCN). Our LCDD+AL cohort consisted of 37 patients (54% females, median age 70 years (range 40-86)). All cases showed Congo red-positive amyloid deposits staining for one light chain isotype on immunofluorescence (62% lambda), and LCDD with diffuse linear staining of glomerular and tubular basement membranes for one light chain isotype (97% same isotype as the amyloidogenic light chain) and ultrastructural non-fibrillar punctate deposits. Twelve of 37 cases (about 1/3 of patients) had concomitant LCCN of same light chain isotype. Proteomic analysis of amyloid and/or LCDD deposits in eight revealed a single light chain variable domain mutable subgroup in all cases (including three with separate microdissections of LCDD and amyloid light chain deposits). Clinical data on 21 patients showed proteinuria (100%), hematuria (75%), kidney insufficiency and nephrotic syndrome (55%). Extra-kidney involvement was present in 43% of the patients. Multiple myeloma occurred in 68% (about 2/3) of these patients; none had lymphoma. On follow up (median 16 months), 63% developed kidney failure and 56% died. The median kidney and patient survivals were 12 and 32 months, respectively. LCDD+AL mainly affected patients 60 years of age or older. Thus, LCDD+AL could be caused by two pathological light chains produced by subclones stemming from one immunoglobulin light chain lambda or kappa rearrangement, with a distinct mutated complementary determining region.

Original languageEnglish (US)
Pages (from-to)152-163
Number of pages12
JournalKidney international
Issue number1
StatePublished - Jan 2022


  • AL amyloidosis
  • MGRS
  • light chain cast nephropathy
  • light chain deposition disease
  • monoclonal gammopathy
  • multiple myeloma

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis'. Together they form a unique fingerprint.

Cite this